{
    "nctId": "NCT00767520",
    "briefTitle": "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer",
    "officialTitle": "A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin\u00c2\u00ae) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 155,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis\n* Prior therapy with a non-steroidal aromatase inhibitor\n* Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)\n* Documented breast cancer with tumor \u2264 28 days prior to study entry\n* Women who are NOT of childbearing potential\n* Must be able to take oral medication\n* Performance Status 0 or 1\n\nExclusion Criteria:\n\n* Pleural or pericardial effusion or ascites (of any etiology; Grade \u2265 1) within 6 months prior to study entry\n* Any chemotherapy, immunotherapy \\< 6 months before study entry. Any targeted therapy (eg. lapatinib) \\< 6 months before study entry, unless given in combination with an NSAI\n* Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry\n* Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer\n* Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years\n* Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding\n* Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction \u2264 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval \\> 450 msec at baseline (Fridericia correction)\n* Hematologic abnormality Grade \u2265 2\n* Hypocalcemia of Grade \u2265 1\n* Any Chemistry abnormality of Grade \u2265 2 \\[except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease\\]\n* Pregnant Women and Women of Childbearing Potential (WOCBP)\n* Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)\n* Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)\n* Potent inhibitors of CYP3A4 isoenzyme\n* Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}